[HTML][HTML] A clinical trial of optimal time interval between ablation and diagnostic activity when a pretherapy RAI scanning is performed on patients with differentiated …
Y Yin, Q Mao, S Chen, N Li, X Li, Y Li - Medicine, 2015 - journals.lww.com
This article investigates the association of the time interval between the diagnostic dose and
ablation with the stunning effect, when a 74 MBq 131 I pretherapy scanning was performed …
ablation with the stunning effect, when a 74 MBq 131 I pretherapy scanning was performed …
Influence of 131I diagnostic dose on subsequent ablation in patients with differentiated thyroid carcinoma: discrepancy between the presence of visually apparent …
YH Hu, PW Wang, ST Wang, CH Lee… - Nuclear medicine …, 2004 - journals.lww.com
Background In the management of patients with differentiated thyroid carcinoma, direct
comparison of the presence of scintigraphic stunning after a diagnostic dose of 131 I with …
comparison of the presence of scintigraphic stunning after a diagnostic dose of 131 I with …
A quantitative study about thyroid stunning after diagnostic whole-body scanning with 74 MBq 131I in patients with differentiated thyroid carcinoma.
Y Yin, Q Mao, S Chen, N Li, X Li, Y Li - … [and] Section of the Society of …, 2015 - europepmc.org
Aim The aim of this paper was to explore by a quantitative method whether a 74 MBq 131I
scanning activity produces a stunning effect in patients with differentiated thyroid carcinoma …
scanning activity produces a stunning effect in patients with differentiated thyroid carcinoma …
No Adverse Affect in Clinical Outcome Using Low Preablation Diagnostic 131I Activity in Differentiated Thyroid Cancer: Refuting Thyroid-Stunning Effect
BK Yap, B Murby - The Journal of Clinical Endocrinology & …, 2014 - academic.oup.com
Context: Published studies of thyroid stunning due to preablation 131I scanning in the
treatment of differentiated thyroid cancer after thyroidectomy had shown inconsistent clinical …
treatment of differentiated thyroid cancer after thyroidectomy had shown inconsistent clinical …
Stunning phenomenon after a radioactive iodine-131 diagnostic whole-body scan: Is it really a point of clinical consideration?
A Amin, M Amin, A Badwey - Nuclear Medicine Communications, 2013 - journals.lww.com
Purpose Stunning of thyroid remnants after diagnostic scanning (Dx-WBS) using radioactive
iodine-131 (131 I) may limit the efficacy of 131 I therapy. We aimed to evaluate this …
iodine-131 (131 I) may limit the efficacy of 131 I therapy. We aimed to evaluate this …
[HTML][HTML] Comparison of radioactive iodine activities in terms of short-and long-term results in ablation therapy in patients with low-risk differentiated thyroid cancer
S Saraçoğlu, O Güven, GB Babacan… - Molecular Imaging …, 2023 - ncbi.nlm.nih.gov
Objectives: The aim of this study was to compare the treatment responses after ablation with
30-50 mCi radioactive iodine (RAI) and 100 mCi RAI in patients with differentiated thyroid …
30-50 mCi radioactive iodine (RAI) and 100 mCi RAI in patients with differentiated thyroid …
The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131I
FA Verburg, RBT Verkooijen… - Nuklearmedizin …, 2009 - thieme-connect.com
Objective: Dosimetry studies have shown that activities of 131 I as small as 10-20 MBq may
cause a stunning effect. A result of this stunning effect may be a lower success rate of the …
cause a stunning effect. A result of this stunning effect may be a lower success rate of the …
Efficacy of low radioiodine activity versus intermediate-high activity in the ablation of low-risk differentiated thyroid cancer
Purpose The aim of our study was to compare the efficacy of thyroid remnant ablation using
low (1.1 GBq) and intermediate-high radioiodine (RAI) activity (1.85–3.7 GBq) in low-risk …
low (1.1 GBq) and intermediate-high radioiodine (RAI) activity (1.85–3.7 GBq) in low-risk …
Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients?
A Piccardo, M Puntoni, G Ferrarazzo, L Foppiani… - European journal of …, 2018 - Springer
Purpose Current guidelines recommend thyroid hormone withdrawal (THW) of 3–4 weeks
before radioiodine remnant ablation (RRA) of differentiated thyroid carcinoma (DTC). We …
before radioiodine remnant ablation (RRA) of differentiated thyroid carcinoma (DTC). We …
Thyroid stunning in radioiodine-131 therapy of benign thyroid diseases
C Happel, WT Kranert, H Ackermann, I Binse… - Endocrine, 2019 - Springer
Purpose Existence and cause of thyroid stunning was controversially discussed for decades
but the underlying mechanism remains unclear. Numerous studies describe thyroid stunning …
but the underlying mechanism remains unclear. Numerous studies describe thyroid stunning …